[go: up one dir, main page]

MX2009006575A - Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids). - Google Patents

Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).

Info

Publication number
MX2009006575A
MX2009006575A MX2009006575A MX2009006575A MX2009006575A MX 2009006575 A MX2009006575 A MX 2009006575A MX 2009006575 A MX2009006575 A MX 2009006575A MX 2009006575 A MX2009006575 A MX 2009006575A MX 2009006575 A MX2009006575 A MX 2009006575A
Authority
MX
Mexico
Prior art keywords
nsaids
ligands
urinary tract
lower urinary
tract disorders
Prior art date
Application number
MX2009006575A
Other languages
English (en)
Inventor
Amedeo Leonardi
Luciano Guarneri
Patrizia Angelico
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of MX2009006575A publication Critical patent/MX2009006575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La administración a un mamífero de una combinación de compuestos, al menos uno de los cuales es un ligando (A2d) de subunidad de canal de calcio a2d y al menos uno de los cuales es un fármaco anti-inflamatorio no esteroidal (NSAID), proporciona una inhibición sorprendente y potente del reflejo de micción, superior a aquella obtenida por tratamiento con un ligando A2d o NSAID solo. Combinaciones de ligando A2d y NSAIDs de esta manera son útiles para el tratamiento de trastornos del tracto urinario inferior y síntomas de los mismos. Los ligandos A2d preferidos son gabapentina y pregabalina. Los NSAIDs preferidos son celecoxib, diclofenaco, diflunisal, flurbiprofeno, naproxeno, nimesulida o sulindaco.
MX2009006575A 2006-12-22 2007-12-21 Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids). MX2009006575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87171906P 2006-12-22 2006-12-22
PCT/EP2007/011313 WO2008077599A1 (en) 2006-12-22 2007-12-21 COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS

Publications (1)

Publication Number Publication Date
MX2009006575A true MX2009006575A (es) 2009-07-02

Family

ID=39272500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006575A MX2009006575A (es) 2006-12-22 2007-12-21 Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).

Country Status (25)

Country Link
US (1) US20080153888A1 (es)
EP (1) EP2125021B8 (es)
JP (1) JP5308350B2 (es)
KR (1) KR20090092307A (es)
CN (2) CN101600458A (es)
AT (1) ATE511860T1 (es)
AU (1) AU2007338367B2 (es)
BR (1) BRPI0720351A2 (es)
CA (1) CA2673545A1 (es)
CY (1) CY1111783T1 (es)
DK (1) DK2125021T3 (es)
EA (1) EA017171B1 (es)
ES (1) ES2367881T3 (es)
HR (1) HRP20110634T1 (es)
IL (1) IL198891A (es)
MX (1) MX2009006575A (es)
NO (1) NO20092581L (es)
NZ (1) NZ577097A (es)
PL (1) PL2125021T3 (es)
PT (1) PT2125021E (es)
RS (1) RS51940B (es)
SI (1) SI2125021T1 (es)
UA (1) UA94979C2 (es)
WO (1) WO2008077599A1 (es)
ZA (1) ZA200905038B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026154A1 (en) * 2008-09-04 2010-03-11 Neurosearch A/S A method for combating adverse effects arising from antipsychotic treatment
US9415048B2 (en) * 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130323288A1 (en) * 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
CN102648915B (zh) * 2011-02-28 2015-04-15 鲁南制药集团股份有限公司 一种治疗或预防神经病理性疼痛的药物组合物
ITMI20121263A1 (it) 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica multistrato
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
CA2951987C (en) 2014-06-16 2017-10-24 Farmaceuticos Rayere, S.A. Pharmaceutical composition that combines an anticonvulsant and a nicotinic acid derivative

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018830A (en) * 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1561411A (en) * 1977-02-25 1980-02-20 Science Union & Cie 2-phenoxyphenyl pyrrolidines and pharmaceutical compositions containing them
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4885367A (en) 1987-11-19 1989-12-05 Taisho Pharmaceutical Co., Ltd. Sulfonanilide compounds
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
ES2165857T3 (es) 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
DK0595546T3 (da) 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivater
CA2297592A1 (en) 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
CA2113787A1 (en) 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
EP0731795B1 (en) 1993-11-30 1999-12-22 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
WO1995030652A1 (en) 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU699593B2 (en) 1995-02-13 1998-12-10 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
WO1996037479A1 (en) 1995-05-26 1996-11-28 F. Hoffmann La Roche Ag Cyclohexanone oxime derivatives
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
AU725035B2 (en) 1995-07-21 2000-10-05 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
DK0848703T3 (da) 1995-07-21 2001-01-02 Nycomed Austria Gmbh Derivater af benzosulfonamider som inhibitorer for enzymet cyclooxygenase II
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
EP0888325B1 (en) 1996-02-07 2002-05-29 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
IL125364A0 (en) 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
KR100512506B1 (ko) 1996-03-14 2005-12-21 워너-램버트 캄파니 엘엘씨 제약제제로서신규한치환시클릭아미노산
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
RS49881B (sr) 1996-07-18 2008-08-07 Merck Frosst Canada Ltd., Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2
WO1998017627A1 (en) 1996-10-23 1998-04-30 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
EP1006114B1 (en) 1997-04-11 2003-01-22 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and cox inhibitors containing them
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
JP2002515915A (ja) 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
ES2253825T3 (es) * 1997-09-08 2006-06-01 Warner-Lambert Company Llc Composiciones analgesicas que comprenden compuestos antiepilepticos y procedimientos para usar las mismas.
US5925769A (en) 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
CN1303059C (zh) 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物
US6080876A (en) 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
IL135313A0 (en) 1997-12-16 2001-05-20 Warner Lambert Co 1-substituted-1-aminomethylcycloalkane derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
JP2002508361A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用
AU759392B2 (en) 1997-12-16 2003-04-10 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
EP1085845A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
SK286806B6 (sk) 1998-10-27 2009-05-07 Abbott Laboratories Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
OA11918A (en) 1999-02-23 2006-04-12 Pfizer Prod Inc Monoamine reuptake inhibitors for treatment of cnsdisorders.
AU3216600A (en) * 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
KR20010103053A (ko) * 1999-04-08 2001-11-17 로즈 암스트롱, 크리스틴 에이. 트러트웨인 요실금 치료 방법
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
MXPA01012319A (es) 1999-06-10 2002-07-22 Warner Lambert Co Acidos 3-propil gama aminobutiricos mono y disubstituidos.
US6376519B1 (en) 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6306861B1 (en) * 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
US6387909B1 (en) * 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
HK1047577B (zh) 1999-10-13 2005-09-16 辉瑞产品公司 用作一元胺重摄取抑制剂的联芳醚衍生物
US6403594B1 (en) * 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) * 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
MXPA03002090A (es) 2000-09-14 2003-06-19 Gruenenthal Gmbh °-tio-aminoacidos.
PE20021046A1 (es) 2000-09-30 2002-12-14 Gruenenthal Chemie Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
GB2367869B (en) 2000-10-14 2004-10-06 Trw Ltd Rear-axle demand for use with front push-through in electrohydraulic (EHB) braking systems
US6359182B1 (en) * 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
TNSN03094A1 (fr) 2001-04-19 2005-12-23 Warner Lambert Co Amino-acides condenses bicycliques ou tricycliques
ES2296956T5 (es) 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
ES2288641T3 (es) 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US20040248979A1 (en) 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005025562A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
CA2595470A1 (en) 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
WO2006090275A1 (en) * 2005-02-24 2006-08-31 Pfizer Limited Treatment of incontinence
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
US12131399B2 (en) 2018-08-16 2024-10-29 Life Technologies Corporation System and method for automated reagent verification

Also Published As

Publication number Publication date
EP2125021A1 (en) 2009-12-02
SI2125021T1 (sl) 2011-09-30
CN101600458A (zh) 2009-12-09
HK1155663A1 (en) 2012-05-25
ES2367881T3 (es) 2011-11-10
CY1111783T1 (el) 2015-10-07
JP5308350B2 (ja) 2013-10-09
HRP20110634T1 (hr) 2011-10-31
IL198891A (en) 2013-04-30
PT2125021E (pt) 2011-07-26
CN102058885A (zh) 2011-05-18
JP2010522139A (ja) 2010-07-01
DK2125021T3 (da) 2011-09-19
CN102058885B (zh) 2013-04-10
RS51940B (sr) 2012-02-29
US20080153888A1 (en) 2008-06-26
EP2125021B1 (en) 2011-06-08
BRPI0720351A2 (pt) 2019-05-14
AU2007338367B2 (en) 2010-05-20
NZ577097A (en) 2012-05-25
AU2007338367A1 (en) 2008-07-03
ZA200905038B (en) 2010-04-28
EA200900868A1 (ru) 2009-12-30
ATE511860T1 (de) 2011-06-15
CA2673545A1 (en) 2008-07-03
IL198891A0 (en) 2010-02-17
WO2008077599A1 (en) 2008-07-03
EA017171B1 (ru) 2012-10-30
KR20090092307A (ko) 2009-08-31
NO20092581L (no) 2009-07-08
PL2125021T3 (pl) 2011-10-31
EP2125021B8 (en) 2012-02-15
UA94979C2 (uk) 2011-06-25

Similar Documents

Publication Publication Date Title
MX2009006575A (es) Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
NZ601529A (en) Tapentadol compositions
JP2010031044A5 (es)
NZ599464A (en) Combination therapies using hdac inhibitors
WO2006128058A3 (en) Thyromimetics for the treatment of fatty liver diseases
WO2002098352A3 (en) PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
JP2009531451A5 (es)
MA29236B1 (fr) Prevention et traitement de troubles thromboemboliques
RU2013145498A (ru) Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
IL186374A (en) Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them
WO2011100659A3 (en) Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
EA201100229A1 (ru) Фармацевтическая композиция для лечения верхнего отдела пищеварительного тракта
JP2010522139A5 (es)
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
JP2007512273A5 (es)
DK2101730T3 (da) Galenisk form til transmucosal indgivelse af paracetamol
UA113841C2 (xx) Сірководневі похідні нестероїдних протизапальних лікарських засобів
RU2016148183A (ru) (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
GEP20074254B (en) Agent for treatment of joint disease
DK1829548T3 (da) Anvendelse af Pelargoniumekstrakter i kombination med Plantago til fremstilling af et medikament til behandling af halsbetændelse
EA200801274A1 (ru) Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана
GEP20074253B (en) Agent for treatment of joint disease
CA2411960A1 (en) Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
RU2015112586A (ru) Фармацевтические композиции, содержащие флурбипрофен

Legal Events

Date Code Title Description
FG Grant or registration